Compile Data Set for Download or QSAR
maximum 50k data
Found 108 Enz. Inhib. hit(s) with all data for entry = 7040
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168079(US9073931, E27a | US9073931, E7a)
Affinity DataKi:  2nM ΔG°:  -49.7kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168122(US9073931, E28)
Affinity DataKi:  5nM ΔG°:  -47.4kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168117(US9073931, E25a)
Affinity DataKi:  6nM ΔG°:  -46.9kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168093(US9073931, E12)
Affinity DataKi:  6nM ΔG°:  -46.9kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168119(US9073931, E26)
Affinity DataKi:  7nM ΔG°:  -46.5kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168088(US9073931, E10b | US9073931, E10c)
Affinity DataKi:  7nM ΔG°:  -46.5kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168088(US9073931, E10b | US9073931, E10c)
Affinity DataKi:  7nM ΔG°:  -46.5kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168113(US9073931, E24a | US9073931, E24b)
Affinity DataKi:  7nM ΔG°:  -46.5kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168104(US9073931, E18)
Affinity DataKi:  8nM ΔG°:  -46.2kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168082(US9073931, E8b | US9073931, E8c)
Affinity DataKi:  9nM ΔG°:  -45.9kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168125(US9073931, E30)
Affinity DataKi:  10nM ΔG°:  -45.7kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168108(US9073931, E21)
Affinity DataKi:  10nM ΔG°:  -45.7kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168109(US9073931, E22a)
Affinity DataKi:  12nM ΔG°:  -45.2kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168082(US9073931, E8b | US9073931, E8c)
Affinity DataKi:  13nM ΔG°:  -45.0kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168079(US9073931, E27a | US9073931, E7a)
Affinity DataKi:  14nM ΔG°:  -44.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168091(US9073931, E11a | US9073931, E11b)
Affinity DataKi:  14nM ΔG°:  -44.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168077(US9073931, E6a)
Affinity DataKi:  14nM ΔG°:  -44.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168094(US9073931, E13a)
Affinity DataKi:  17nM ΔG°:  -44.3kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168085(US9073931, E9a)
Affinity DataKi:  17nM ΔG°:  -44.3kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168113(US9073931, E24a | US9073931, E24b)
Affinity DataKi:  20nM ΔG°:  -43.9kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168111(US9073931, E23a)
Affinity DataKi:  21nM ΔG°:  -43.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168091(US9073931, E11a | US9073931, E11b)
Affinity DataKi:  23nM ΔG°:  -43.6kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168079(US9073931, E27a | US9073931, E7a)
Affinity DataKi:  23nM ΔG°:  -43.6kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168122(US9073931, E28)
Affinity DataKi:  26nM ΔG°:  -43.3kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168119(US9073931, E26)
Affinity DataKi:  46nM ΔG°:  -41.9kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168093(US9073931, E12)
Affinity DataKi:  49nM ΔG°:  -41.7kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168098(US9073931, E15a | US9073931, E29a)
Affinity DataKi:  50nM ΔG°:  -41.7kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168113(US9073931, E24a | US9073931, E24b)
Affinity DataKi:  56nM ΔG°:  -41.4kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168082(US9073931, E8b | US9073931, E8c)
Affinity DataKi:  65nM ΔG°:  -41.0kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168104(US9073931, E18)
Affinity DataKi:  70nM ΔG°:  -40.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168088(US9073931, E10b | US9073931, E10c)
Affinity DataKi:  72nM ΔG°:  -40.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168082(US9073931, E8b | US9073931, E8c)
Affinity DataKi:  74nM ΔG°:  -40.7kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168117(US9073931, E25a)
Affinity DataKi:  83nM ΔG°:  -40.4kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168108(US9073931, E21)
Affinity DataKi:  83nM ΔG°:  -40.4kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168088(US9073931, E10b | US9073931, E10c)
Affinity DataKi:  106nM ΔG°:  -39.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168106(US9073931, E20a)
Affinity DataKi:  110nM ΔG°:  -39.7kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168125(US9073931, E30)
Affinity DataKi:  129nM ΔG°:  -39.3kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168085(US9073931, E9a)
Affinity DataKi:  136nM ΔG°:  -39.2kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168075(US9073931, E4)
Affinity DataKi:  137nM ΔG°:  -39.2kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168109(US9073931, E22a)
Affinity DataKi:  149nM ΔG°:  -39.0kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168091(US9073931, E11a | US9073931, E11b)
Affinity DataKi:  160nM ΔG°:  -38.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168073(US9073931, E2)
Affinity DataKi:  176nM ΔG°:  -38.6kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168072(US9073931, E1)
Affinity DataKi:  191nM ΔG°:  -38.3kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168113(US9073931, E24a | US9073931, E24b)
Affinity DataKi:  198nM ΔG°:  -38.3kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168102(US9073931, E17a)
Affinity DataKi:  220nM ΔG°:  -38.0kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168091(US9073931, E11a | US9073931, E11b)
Affinity DataKi:  236nM ΔG°:  -37.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168111(US9073931, E23a)
Affinity DataKi:  237nM ΔG°:  -37.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-beta(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168098(US9073931, E15a | US9073931, E29a)
Affinity DataKi:  240nM ΔG°:  -37.8kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168079(US9073931, E27a | US9073931, E7a)
Affinity DataKi:  253nM ΔG°:  -37.7kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOxysterols receptor LXR-alpha(Homo sapiens (Human))
Vitae Pharmaceuticals

US Patent
LigandPNGBDBM168077(US9073931, E6a)
Affinity DataKi:  277nM ΔG°:  -37.4kJ/moleT: 2°CAssay Description:Compounds of the invention were assessed in a competition binding assay where different concentrations of compounds were incubated with the LXR ligan...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 108 total ) | Next | Last >>
Jump to: